1. Generics Bulletin
  2. >>Products

Interchangeable Biosimilars May Qualify For ‘Immediate Substitution’ In Medicare Part D

 
• By Cathy Kelly

Proposed policy could help promote uptake of interchangeable biosimilars to AbbVie’s blockbuster Humira. However, some PBMs and insurers are not persuaded that interchangeability is a useful distinction so may not rush to take advantage of the new flexibility.

Part D interchangeable
Immediate Substitution Not Allowed For Non-Interchangeable Biosimilars • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

Beginning in 2024, Medicare Part D plans would be permitted to substitute interchangeable biosimilars as soon as they are available, without waiting for the beginning of the next benefit year, under a proposed rule released by the Centers for Medicare and Medicaid Services on 14 December.

The policy is included in the Contract Year 2024 Policy and Technical Changes to the Medicare Advantage Program and Medicare...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products